|
Orthologous residues
|
|
PSF (human): T687‑p, PSF (mouse): T679‑p, PSF (rat): T679‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
JSL1 (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
GSK3B (human)
|
transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
decrease
|
|
|
SB216763
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
BCLAF1 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
Trap150 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
TRAP150-PSF interaction regulates CD45 splicing by blocking PSF from interacting with CD45 pre-mRNA in resting T cells
|
